Search

Filters

Clear Filters
12:10 PM - 12:15 PM PT

1163 - PSMA PET Nodule Discordance Yields Suboptimal Dosimetric Coverage in Patients with High-Risk Prostate Cancer Treated with MRI based SBRT and Intraprostatic Boost
Speaker: Kavadi, Raj, DO, MS - Tufts Medical Center, Boston, MA
12:15 PM - 12:20 PM PT

1164 - Novel Cardiac Radiomics Using PET Imaging and Deep Learning to Predict Post-Radiotherapy Cardiac Toxicity for Lung Cancer Patients
Speaker: Cao, Wenchao, PhD - Thomas Jefferson University, Philadelphia, PA
12:20 PM - 12:25 PM PT

1165 - Multimodal Pre-Guided Observation of Rectal Gas and OAR Dose Differences in Intracavitary Brachytherapy for Cervical Cancer: A Prospective Randomized Controlled Study
Speaker: Ma, Juan - Department of Radiation Oncology, Xijing Hospital, Fourth Military Medical University., Xi’an, shaanxi
12:25 PM - 12:30 PM PT

1166 - Pioneering Proton FLASH-Minibeam Therapy: First Experimental Demonstration of Feasibility on a Clinical Proton System
Speaker: Lin, Yuting, PhD - Department of Radiation Oncology, University of Kansas Medical Center, Kansas City, KS
12:30 PM - 12:35 PM PT

1167 - Neural Reconstruction for Super-Resolution Radiotherapy QA from Sparse Dosimeter Arrays
Speaker: Wang, Siqi, PhD - Stanford, Stanford, CA
3:00 PM - 3:10 PM PT

117 - Outcomes Following Radiation Therapy and Radical Prostatectomy in Patients with High Risk Prostate Cancer in a Similar Access System
Speaker: Kumar, Abhishek, MD, MAS - The Oncology Institute of Hope and Innovation, Cerritos, CA
3:10 PM - 3:20 PM PT

118 - Phase III Study of Hypofractionated, Dose Escalation Radiotherapy vs. Conventional Pelvic Radiation Therapy followed by High Dose Rate Brachytherapy Boost for High Risk Adenocarcinoma of the Prostate (PCS VI)
Speaker: Niazi, Tamim, MD - McGill University, Montreal, QC
3:20 PM - 3:30 PM PT

119 - Conventional vs. Hypofractionated, Radiotherapy for High-Risk Prostate Cancer: 10-Year Outcomes of the Randomized, Non-Inferiority, Phase 3 PCS5 Trial
Speaker: Niazi, Tamim, MD - McGill University, Montreal, QC
3:30 PM - 3:35 PM PT

120 - 5-Year Results of a Prospective, Non-Randomized Controlled Study: Comparison of the Efficacy and Safety of ADT + Docetaxel vs. ADT + Novel Hormone Therapy in High Gleason Score Non-Metastatic Prostate Cancer Patients Receiving Radiotherapy
Speaker: Ma, Mingwei, MD - Peking University First Hospital, Beijing, Beijing
2:30 PM - 2:37 PM PT

121 - Impact of MMR Status vs. Clinicopathologic Risk Factors on Locoregional Recurrence in Stage I Endometrioid Endometrial Cancer Treated with Brachytherapy Alone
Speaker: Hathout, Lara, MD, FRCPC - Rutgers Cancer Institute , New Brunswick, NJ
2:37 PM - 2:44 PM PT

122 - Radiation-Induced CTD-2292M14.1 Enhances Cervical Cancer Radioresistance by Promoting P62 Ubiquitination
Speaker: Zhou, Jie, PhD, RT - Sichuan Cancer Hospital and Institute, Chengdu, Sichuan
2:44 PM - 2:51 PM PT

123 - Transcriptomic Profiling Reveals Predictive Markers of Response to Concurrent Chemoradiotherapy plus Immune Checkpoint Inhibition in Cervical Cancer
Speaker: Cao, Yuan Jie, MD, PhD - Tianjin Medical University Cancer Institute and Hospital, Tian Jin, Tian Jin